Microba Secures $5 Million to Drive Diagnostics Growth and Reach Break-Even by 2027

Capital Raise Fuels Path to Profitability

Microba Life Sciences Limited (ASX:MAP) has successfully raised $5 million through a two-tranche placement priced at $0.05 per share, a notable 20.6% discount to its last close. The raise attracted strong support from both existing and new institutional investors, including strategic shareholder Sonic Healthcare Limited, which committed $1.5 million. Alongside the placement, Microba is launching a $1 million Share Purchase Plan (SPP) for eligible shareholders, also at $0.05 per share, both accompanied by attaching options exercisable at $0.0625 within three years, pending shareholder approval.

This capital injection is earmarked to underpin Microba’s ambitious goal of achieving company-wide cashflow break-even by the end of calendar year 2027. The company’s strategy hinges on leveraging recent infrastructure investments and AI-driven operational efficiencies to reduce its current monthly cash burn of approximately $1.3 million. Cost savings of around $700,000 per month are expected from streamlined operations, while revenue and margin growth are forecast to contribute an additional $600,000 monthly, together closing the gap to break-even.

Diagnostic Sales Momentum and Product Innovation

Microba’s core diagnostics business continues to impress with 11 consecutive quarters of sales growth, including a 106% increase in core testing sales over the past 12 months. This momentum is driven by a growing pipeline of enterprise-style healthcare clinic contracts across Australia and the UK, with the UK market notably outperforming Australia at a similar stage post-launch. The company has achieved an annualised test run rate exceeding 23,000, with over 22,000 additional tests anticipated from recently signed contracts.

Looking ahead, Microba plans to launch a category-defining new testing product in Q3 2026, designed to support the 40% of people living with unresolved gastrointestinal disorders. This product aims to simplify result interpretation for healthcare professionals through advanced clinical intelligence, positioning Microba to accelerate adoption among mainstream medical practitioners.

Therapeutics Division Ready for Partnering

Beyond diagnostics, Microba’s therapeutics division is advancing a diversified portfolio of microbiome-derived live biotherapeutic products, including the Phase 2-ready MAP 315 targeting ulcerative colitis, a market valued at over US$10 billion. The division is actively engaged in a partnering process with a Boston-based specialist advisory firm, following multiple positive clinical trial readouts in the microbiome therapeutics sector. This strategic move underscores Microba’s intent to capitalise on the growing interest and investment in microbiome-based therapeutics globally.

Corporate Interest and Strategic Decisions

Microba recently entertained an approach from a UK-based private equity fund for the divestment of its Diagnostics and Supplements businesses. After extensive due diligence, terms were agreed in principle, with the proposed consideration exceeding Microba’s market capitalisation at the time. However, the company ultimately decided not to proceed, citing the final deal structure as not aligning with shareholder interests.

The placement shares will be issued in two tranches, with the first tranche utilising existing placement capacity and the second tranche, along with all attaching options, subject to shareholder approval at a general meeting scheduled for late July 2026. The company has appointed Morgans Corporate Limited and Canaccord Genuity (Australia) Limited as joint lead managers for the placement.